P PRIMESTOCKFINDER.COM

AMPH Stock Amphastar Pharmaceuticals, Inc.

US · NasdaqGS
$25.47 +1.31% Prices as of close 2026-10-27

Last in our picks 2026-10-09 — not in the current list; analysis below is from that screen

Specialty-drug pipeline offers upside, though consensus remains cautious and risk is elevated.

Future value: $22.50 (-12.82%) · 6-12 months · analyst consensus

Signal breakdown

  • ▸Wall Street Zen upgraded shares, but broader analyst consensus remains Reduce.
  • ▸Above 50-day MA (+12.45%)
  • ▸Above 200-day MA — long-term uptrend
  • ▾Trading above its price target — limited upside

Is AMPH a buy right now?

Trend: AMPH is trading above the 50-day average (+4.60%), RSI 27 — oversold territory, with a 3-month return of +26.40%.

Valuation & quality: Amphastar Pharmaceuticals, Inc. trades on a trailing P/E of 15.1, forward P/E 8.0, price-to-book 1.41; fundamentals show net margin 10.8%, return on equity 10.3%, revenue growth 5.4% year on year.

Analyst consensus: 6 analysts have a mean 12-month price target of $22.50 (-11.7% vs the last close; range $20.00 – $30.00), consensus rating “hold”.

Our screen: WATCH (score 0) — Specialty-drug pipeline offers upside, though consensus remains cautious and risk is elevated.

Computed from end-of-day data; not personal advice.

12-month price chart

28.7 16.9 FebMarAprMayJunJulAugSepOct
Daily close, 2026-02-09 → 2026-10-26 (USD). Range 16.9 – 28.7.

Monthly returns

Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26
-3.20%+12.10%-14.20%+7.10%-1.20%+13.00%+14.60%-1.30%

Fundamentals

Market cap
$1.08B
P/E (ttm)
15.1
Forward P/E
8.0
EPS (ttm)
$1.69
Price / book
1.41
Beta
0.90
Net margin
10.8%
ROE
10.3%
Revenue growth
5.4%
Earnings growth
4.7%
Revenue (ttm)
$730.0M
Free cash flow
$230.1M
Debt / equity
90%
52-wk range
$16.65 – $29.52
Volume
225,240
Avg volume (3m)
458,273

Analyst price target

Mean target
$22.50
Low
$20.00
High
$30.00
Analysts
6
Consensus
HOLD

Technical signals

RSI (14)
27.1
vs 50-day MA
+4.60%
1-mo return
-2.53%
3-mo return
+26.40%
Volume z-score
-0.73

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.

Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · United States · 1,976 employees · Website

Related Health Care picks

BMRNBioMarin PharmaceuticaIONSIonis Pharmaceuticals,BSXBoston Scientific CorpSYKStryker CorporationUNHUnitedHealth Group IncHUMHumana Inc.BMYBristol-Myers Squibb CHNGEHinge Health, Inc.

Browse: all US stocks · Health Care picks · today's movers

Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.